CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]. ASSET PURCHASE AGREEMENT...Asset Purchase Agreement • August 16th, 2021 • Fortress Biotech, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 16th, 2021 Company Industry JurisdictionTHIS ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of March 31, 2021, is made by and between Journey Medical Corporation, a Delaware corporation (“Buyer”), and Dermira, Inc., a Delaware corporation (“Seller”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]. ASSET PURCHASE AGREEMENTAsset Purchase Agreement • August 16th, 2021 • Fortress Biotech, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 16th, 2021 Company Industry JurisdictionThis ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 23, 2021 (the “Effective Date”), by and between Sentynl Therapeutics, Inc., a Delaware corporation (“Sentynl”), and Cyprium Therapeutics, Inc., a Delaware corporation (“Cyprium”). Each of Cyprium and Sentynl is a “Party,” and they are, collectively, the “Parties.”